| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13dbf3f9556810ecea37f259703ccab7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate |
2016-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ca21d590bdbb89964574f9d63babd5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1daf2035965fb965fe0c9a16d175ba9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba09cd38e591849358a037266da1bb7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_521672c04f5a9ee42eca599aaf1cff12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59eb7a62286e7d0bc8b2f9378c136afe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bf7680e3ecbfb545a5befdd256c6fca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12010dfdbe3a41eee7c7d6f5a5ff3672 |
| publicationDate |
2017-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017260264-A1 |
| titleOfInvention |
Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
| abstract |
The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half-life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020204105-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11655292-B2 |
| priorityDate |
2009-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |